ATLANTA, GA — (Marketwired) — 05/21/15 — Corporate Media Straight Talk announced today that a new audio interview with Isoray, Inc. (NYSE: ISR) CEO Dwight Babcock is now available for listening. The interview can be heard at .
IsoRay, Inc. CEO Dwight Babcock called in to Corporate Media Straight Talk.com to provide the listening audience with his own insights into the recent press release dated April 20th, 2015, entitled:
“IsoRay–s Cesium-131 Lung Cancer Treatment Reports 96% Success In Local Control And 100% Survival At 5 Years in High Risk Patients In Newly Published Report.”
Corporate Media Straight Talk is a multimedia platform that enables senior management of public companies with the opportunity to speak about their recent press releases and corporate developments. Corporate Media Straight Talk offers the public the opportunity to actually listen and watch CEOs of public companies talk about their respective businesses and news on a frequent and ongoing basis.
This news release contains certain “forward-looking statements.” Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company–s control. The forward-looking statements are also identified through the use of words “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company–s periodic reports filed with the U.S. Securities and Exchange Commission via the Edgar system. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.
Read more at
For more information:
Corporate Media Straight Talk
678-878-3100
You must be logged in to post a comment Login